# KLF12

## Overview
KLF12, or Krüppel-like factor 12, is a gene that encodes a zinc finger transcription factor involved in the regulation of gene expression. The KLF12 protein, also known as AP-2rep, functions primarily as a transcriptional repressor, playing a critical role in various cellular processes such as proliferation, differentiation, and apoptosis. It is characterized by its three Gli-Kruppel C2H2-type zinc finger domains, which facilitate DNA binding and gene silencing during tissue differentiation (Roth2000Genomic). KLF12 is implicated in several physiological and pathological contexts, including its involvement in decidualization, erythroid differentiation, and cancer progression. The gene's dysregulation has been associated with various cancers, where it influences tumor growth and metastasis through interactions with other proteins and signaling pathways (Li2023KLF12; Shen2013Krüppellike).

## Structure
The KLF12 protein, also known as AP-2rep, is a transcriptional repressor characterized by its molecular structure, which includes three Gli-Kruppel C2H2-type zinc finger domains. These zinc fingers are crucial for the protein's DNA binding capability and its role in gene silencing during tissue differentiation (Roth2000Genomic). The primary structure of KLF12 consists of 402 amino acids, showing high similarity to its murine counterpart (Roth2000Genomic). 

The protein also contains a serine- and threonine-rich domain, which may be involved in post-translational modifications such as phosphorylation, potentially affecting the protein's function and stability (Roth2000Genomic). Additionally, KLF12 features a PVDLS motif that interacts with the transcriptional corepressor CtBP2, indicating a role in transcriptional repression through protein-protein interactions (Roth2000Genomic).

The genomic structure of KLF12 is complex, comprising seven exons separated by large introns, and is located on chromosome 13q22 (Roth2000Genomic). While specific details on the secondary, tertiary, and quaternary structures are not provided, the presence of zinc finger domains suggests a folded structure that facilitates DNA binding. The study also notes the existence of splice variants, which may result in different isoforms with distinct functions, although specific variants are not detailed in the context provided.

## Function
KLF12, also known as Krüppel-like factor 12, is a zinc finger transcription factor involved in various molecular processes within healthy human cells. It functions primarily as a transcriptional repressor, binding to specific DNA sequences to modulate gene expression. KLF12 is known to negatively regulate the process of decidualization in human endometrial stromal cells (HESCs), which is crucial for successful uterine implantation and pregnancy. During decidualization, KLF12 expression decreases, and its overexpression represses the expression of key decidualization markers such as prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1) (Shen2013Krüppellike).

KLF12 also plays a role in erythroid differentiation, where its expression is reduced upon induction, suggesting a negative regulatory role in the expression of the γ-globin gene (Zhang2005A). The protein is active in the nucleus, where it interacts with co-repressors such as the C-terminal binding protein (CtBP) family to mediate transcriptional repression (Kaczynski2003Sp1andKrüppelliketranscriptionfactors). KLF12's activity is associated with cellular processes like proliferation, differentiation, and apoptosis, influencing various physiological outcomes (Swamynathan2010Krüppellike).

## Clinical Significance
KLF12 (Kruppel-like factor 12) has been implicated in the progression of several cancers due to alterations in its expression levels and interactions. In poorly differentiated gastric cancer, KLF12 is overexpressed in a significant number of cases, correlating with tumor size and suggesting its role in cancer progression. Knockdown of KLF12 in gastric cancer cell lines results in growth arrest, indicating its potential as a therapeutic target (Nakamura2009Krüppel‐like).

In breast cancer, KLF12 promotes cell proliferation by repressing the transcription of p21, both in p53-dependent and independent manners. It reduces p53 protein stability, leading to enhanced tumor growth and poorer prognosis in patients with high KLF12 expression (Li2023KLF12).

KLF12 is also overexpressed in endometrial cancer, where it activates the AKT signaling pathway, enhancing cell proliferation and migration while reducing apoptosis. This overexpression is associated with poor prognosis and disease recurrence (Ding2019Dysregulation).

In ovarian cancer, KLF12 is targeted by microRNA-650, which suppresses its expression. KLF12 knockdown inhibits cell viability and promotes apoptosis, suggesting its role in cancer cell proliferation and metastasis (Lu2022MicroRNA650).

## Interactions
KLF12 interacts with several proteins and nucleic acids, playing a significant role in various cellular processes. In breast cancer cells, KLF12 interacts with the tumor suppressor protein p53, inhibiting its acetylation by blocking the interaction between p53 and the coactivator p300. This inhibition occurs at specific lysine residues, leading to reduced p53 stability and increased ubiquitination and degradation (Li2023KLF12). KLF12 also directly binds to the promoter of the p21 gene, acting as a transcriptional repressor, which affects cell proliferation in both p53-dependent and p53-independent manners (Li2023KLF12).

In pancreatic cancer, KLF12 regulates the Wnt/β-catenin signaling pathway by binding to the promoter regions of DVL2, a component of the pathway, thereby preventing β-catenin degradation and promoting its nuclear translocation (He2019MicroRNA137). In colorectal cancer, KLF12 enhances tumor growth by activating early growth response protein 1 (EGR1) through direct binding to its promoter (Kim2016KrüppelLike).

KLF12 also interacts with Galectin-1 (Gal-1) in the context of cancer immunotherapy resistance. It binds to the Gal-1 promoter, inhibiting its transcription, which enhances CD8+ T-cell infiltration and function, potentially improving responses to anti-PD-1 therapy (Zheng2023KLF12).


## References


[1. (Kaczynski2003Sp1andKrüppelliketranscriptionfactors) Joanna Kaczynski, Tiffany Cook, and Raul Urrutia. Sp1-and krüppel-like transcription factors. Genome Biology, 4(2):206, 2003. URL: http://dx.doi.org/10.1186/gb-2003-4-2-206, doi:10.1186/gb-2003-4-2-206. This article has 1178 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/gb-2003-4-2-206)

[2. (Shen2013Krüppellike) Xiaoyue Shen, Yali Hu, Yue Jiang, Hongyu Liu, Lihua Zhu, Xiaoyan Jin, Huizhi Shan, Xin Zhen, Lihua Sun, Guijun Yan, and Haixiang Sun. Krüppel-like factor 12 negatively regulates human endometrial stromal cell decidualization. Biochemical and Biophysical Research Communications, 433(1):11–17, March 2013. URL: http://dx.doi.org/10.1016/j.bbrc.2013.02.078, doi:10.1016/j.bbrc.2013.02.078. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2013.02.078)

[3. (Ding2019Dysregulation) Ling Ding, Yi Ding, Xiangyi Kong, Jun Wu, Jian Fu, Guijun Yan, and Huaijun Zhou. Dysregulation of krüppel-like factor 12 in the development of endometrial cancer. Gynecologic Oncology, 152(1):177–184, January 2019. URL: http://dx.doi.org/10.1016/j.ygyno.2018.10.028, doi:10.1016/j.ygyno.2018.10.028. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ygyno.2018.10.028)

[4. (Kim2016KrüppelLike) Sun-Hee Kim, Yun-Yong Park, Sung-Nam Cho, Ofer Margalit, Dingzhi Wang, and Raymond N. DuBois. Krüppel-like factor 12 promotes colorectal cancer growth through early growth response protein 1. PLOS ONE, 11(7):e0159899, July 2016. URL: http://dx.doi.org/10.1371/journal.pone.0159899, doi:10.1371/journal.pone.0159899. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0159899)

[5. (Zheng2023KLF12) Yujia Zheng, Hao Zhang, Chu Xiao, Ziqin Deng, Tao Fan, Bo Zheng, Chunxiang Li, and Jie He. Klf12 overcomes anti-pd-1 resistance by reducing galectin-1 in cancer cells. Journal for ImmunoTherapy of Cancer, 11(8):e007286, August 2023. URL: http://dx.doi.org/10.1136/jitc-2023-007286, doi:10.1136/jitc-2023-007286. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jitc-2023-007286)

[6. (He2019MicroRNA137) Zhiwei He, Xingjun Guo, She Tian, Changhao Zhu, Shiyu Chen, Chao Yu, Jianxin Jiang, and Chengyi Sun. Microrna-137 reduces stemness features of pancreatic cancer cells by targeting klf12. Journal of Experimental &amp; Clinical Cancer Research, March 2019. URL: http://dx.doi.org/10.1186/s13046-019-1105-3, doi:10.1186/s13046-019-1105-3. This article has 39 citations.](https://doi.org/10.1186/s13046-019-1105-3)

[7. (Swamynathan2010Krüppellike) Shivalingappa K Swamynathan. Krüppel-like factors: three fingers in control. Human Genomics, 4(4):263, 2010. URL: http://dx.doi.org/10.1186/1479-7364-4-4-263, doi:10.1186/1479-7364-4-4-263. This article has 71 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1479-7364-4-4-263)

[8. (Zhang2005A) Ping Zhang, Priyadarshi Basu, Latasha C. Redmond, Pamela E. Morris, Jeremy W. Rupon, Gordon D. Ginder, and Joyce A. Lloyd. A functional screen for krüppel-like factors that regulate the human γ-globin gene through the caccc promoter element. Blood Cells, Molecules, and Diseases, 35(2):227–235, September 2005. URL: http://dx.doi.org/10.1016/j.bcmd.2005.04.009, doi:10.1016/j.bcmd.2005.04.009. This article has 53 citations.](https://doi.org/10.1016/j.bcmd.2005.04.009)

[9. (Nakamura2009Krüppel‐like) Yu Nakamura, Toshiro Migita, Fumie Hosoda, Naoko Okada, Masahiro Gotoh, Yasuhito Arai, Michiyo Fukushima, Misao Ohki, Satoshi Miyata, Kengo Takeuchi, Issei Imoto, Hitoshi Katai, Toshiharu Yamaguchi, Johji Inazawa, Setsuo Hirohashi, Yuichi Ishikawa, and Tatsuhiro Shibata. Krüppel‐like factor 12 plays a significant role in poorly differentiated gastric cancer progression. International Journal of Cancer, 125(8):1859–1867, July 2009. URL: http://dx.doi.org/10.1002/ijc.24538, doi:10.1002/ijc.24538. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.24538)

[10. (Li2023KLF12) Yanan Li, Shujing Li, Xiaoxia Shi, Zhiqiang Xin, Yuxi Yang, Binggong Zhao, Yvlin Li, Linlin Lv, Ping Ren, and Huijian Wu. Klf12 promotes the proliferation of breast cancer cells by reducing the transcription of p21 in a p53-dependent and p53-independent manner. Cell Death &amp; Disease, May 2023. URL: http://dx.doi.org/10.1038/s41419-023-05824-x, doi:10.1038/s41419-023-05824-x. This article has 6 citations.](https://doi.org/10.1038/s41419-023-05824-x)

[11. (Lu2022MicroRNA650) Xiaoyan Lu, Yun Han, Yuwen Han, Menghui Huang, Jun You, Yinglei Liu, Yingying Ding, and Yanli Zheng. Microrna-650 suppresses klf12 expression to regulate growth and metastasis of human ovarian cancer cells. Acta Biochimica Polonica, October 2022. URL: http://dx.doi.org/10.18388/abp.2020_5987, doi:10.18388/abp.2020_5987. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.18388/abp.2020_5987)

[12. (Roth2000Genomic) Christina Roth, Marion Schuierer, Kalle Günther, and Reinhard Buettner. Genomic structure and dna binding properties of the human zinc finger transcriptional repressor ap-2rep (klf12). Genomics, 63(3):384–390, February 2000. URL: http://dx.doi.org/10.1006/GENO.1999.6084, doi:10.1006/geno.1999.6084. This article has 67 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/GENO.1999.6084)